Basic Information
RNALocate ID: | RLID:11001826 |
RNA Symbol: | hsa-miR-152-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-152 |
RNA ID: | miRBase:MIMAT0000438 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001792 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001793 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001794 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001795 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001796 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:11001822 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001823 | Exosome | Ovarian follicular fluid | 22116803 |
RLID:11001824 | Exosome | Breast milk | 22211110 |
RLID:11001825 | Exosome | Brain tissue | 23382797 |
RLID:11001827 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11001828 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000087 | Exosome | Breast milk|Tongue tissue | |
RLID-D:11000366 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-152-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-17001 |
MNDR | hsa-miR-152-3p | Oral squamous cell carcinoma | MNDR-E-MI-17002 |
MNDR | hsa-miR-152-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-17003 |
MNDR | hsa-miR-152-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-17004 |
MNDR | hsa-miR-152-3p | Lymphoma | MNDR-E-MI-17005 |
MNDR | hsa-miR-152-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-17006 |
MNDR | hsa-miR-152-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-17007 |
MNDR | hsa-miR-152-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-17008 |
MNDR | hsa-miR-152-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-17009 |
MNDR | hsa-miR-152-3p | Her2-receptor positive breast cancer | MNDR-E-MI-17010 |
MNDR | hsa-miR-152-3p | Niemann-pick disease type c | MNDR-E-MI-17011 |
MNDR | hsa-miR-152-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-17012 |
MNDR | hsa-miR-152-3p | Prostate cancer | MNDR-E-MI-17013 |
MNDR | hsa-miR-152-3p | Gastric cancer | MNDR-E-MI-17014 |
MNDR | hsa-miR-152-3p | Alzheimer disease | MNDR-E-MI-17015 |
MNDR | hsa-miR-152-3p | Bladder cancer | MNDR-E-MI-17016 |
MNDR | hsa-miR-152-3p | Dysautonomia familial | MNDR-E-MI-17017 |
MNDR | hsa-miR-152-3p | Head and neck cancer | MNDR-E-MI-17018 |
MNDR | hsa-miR-152-3p | Dengue disease | MNDR-E-MI-17019 |
MNDR | hsa-miR-152-3p | Cardiovascular disease | MNDR-E-MI-17020 |
MNDR | hsa-miR-152-3p | Carotid stenosis | MNDR-E-MI-17021 |
MNDR | hsa-miR-152-3p | Brain cancer | MNDR-E-MI-17022 |
MNDR | hsa-miR-152-3p | Lung cancer | MNDR-E-MI-17023 |
MNDR | hsa-miR-152-3p | Endometrial cancer | MNDR-E-MI-17024 |
MNDR | hsa-miR-152-3p | Parkinson disease | MNDR-E-MI-17025 |
MNDR | hsa-miR-152-3p | Niemann-pick disease | MNDR-E-MI-17026 |
MNDR | hsa-miR-152-3p | Breast cancer | MNDR-E-MI-17027 |
MNDR | hsa-miR-152-3p | Thyroid cancer | MNDR-E-MI-17028 |
MNDR | hsa-miR-152-3p | Pancreatic cancer | MNDR-E-MI-17029 |
MNDR | hsa-miR-152-3p | Malignant melanoma | MNDR-E-MI-17030 |
MNDR | hsa-miR-152-3p | Gaucher disease | MNDR-E-MI-17031 |
MNDR | hsa-miR-152-3p | Rectum adenocarcinoma | MNDR-E-MI-17032 |
MNDR | hsa-miR-152-3p | Nephroblastoma | MNDR-E-MI-17033 |
MNDR | hsa-miR-152-3p | Colon cancer | MNDR-E-MI-17034 |
MNDR | hsa-miR-152-3p | Colon adenocarcinoma | MNDR-E-MI-17035 |
MNDR | hsa-miR-152-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-17036 |
MNDR | hsa-miR-152-3p | Familial ovarian cancer | MNDR-E-MI-17037 |
MNDR | hsa-miR-152-3p | Prostate adenocarcinoma | MNDR-E-MI-17038 |
MNDR | hsa-miR-152-3p | Hematologic cancer | MNDR-E-MI-17039 |
MNDR | hsa-miR-152-3p | Carcinoma ductal breast | MNDR-E-MI-17040 |
MNDR | hsa-miR-152-3p | Glioblastoma | MNDR-E-MI-17041 |
MNDR | hsa-miR-152-3p | Glioma | MNDR-E-MI-17042 |
MNDR | hsa-miR-152-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-17043 |
MNDR | hsa-miR-152-3p | Meningioma | MNDR-E-MI-17044 |
MNDR | hsa-miR-152-3p | Liver neoplasms | MNDR-E-MI-17045 |
MNDR | hsa-miR-152-3p | Cervical adenocarcinoma | MNDR-E-MI-17046 |
MNDR | hsa-miR-152-3p | Gastric adenocarcinoma | MNDR-E-MI-17047 |
MNDR | hsa-miR-152-3p | Lung carcinoma | MNDR-E-MI-17048 |
MNDR | hsa-miR-152-3p | Lung squamous cell carcinoma | MNDR-E-MI-17049 |
MNDR | hsa-miR-152-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-17050 |
MNDR | hsa-miR-152-3p | Lung adenocarcinoma | MNDR-E-MI-17051 |
MNDR | hsa-miR-152-3p | Thyroid carcinoma | MNDR-E-MI-17052 |
MNDR | hsa-miR-152-3p | Ovarian carcinoma | MNDR-E-MI-17053 |
MNDR | hsa-miR-152-3p | Bladder urothelial carcinoma | MNDR-E-MI-17054 |
MNDR | hsa-miR-152-3p | Pancreatic adenocarcinoma | MNDR-E-MI-17055 |
MNDR | hsa-miR-152-3p | Carcinoma renal cell | MNDR-E-MI-17056 |
MNDR | hsa-miR-152-3p | Renal clear cell carcinoma | MNDR-E-MI-17057 |
MNDR | hsa-miR-152-3p | Cholangiocarcinoma | MNDR-E-MI-17058 |
MNDR | hsa-miR-152-3p | Esophageal cancer | MNDR-E-MI-17059 |
MNDR | hsa-miR-152-3p | Liver cirrhosis | MNDR-E-MI-17060 |
MNDR | hsa-miR-152-3p | Lung small cell carcinoma | MNDR-E-MI-17061 |
MNDR | hsa-miR-152-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-17062 |
MNDR | hsa-miR-152-3p | Breast invasive carcinoma | MNDR-E-MI-17063 |
MNDR | hsa-miR-152-3p | Early hepatocellular carcinoma | MNDR-E-MI-17064 |
MNDR | hsa-miR-152-3p | Familiar ovarian carcinoma | MNDR-E-MI-17065 |
MNDR | hsa-miR-152-3p | B-cell lymphoma | MNDR-E-MI-17066 |
MNDR | hsa-miR-152-3p | Rheumatoid arthritis | MNDR-E-MI-17067 |
MNDR | hsa-miR-152-3p | Neuroblastoma | MNDR-E-MI-17068 |
MNDR | hsa-miR-152-3p | Chronic fatigue syndrome | MNDR-E-MI-17069 |
MNDR | hsa-miR-152-3p | Hodgkin lymphoma | MNDR-E-MI-17070 |
MNDR | hsa-miR-152-3p | Neuromyelitis optica | MNDR-E-MI-17071 |
MNDR | hsa-miR-152-3p | Acute myeloid leukemia | MNDR-E-MI-17072 |
MNDR | hsa-miR-152-3p | Colorectal cancer | MNDR-E-MI-17073 |
MNDR | hsa-miR-152-3p | Nasopharynx carcinoma | MNDR-E-MI-17074 |
MNDR | hsa-miR-152-3p | Type 2 diabetes mellitus | MNDR-E-MI-17075 |
MNDR | hsa-miR-152-3p | Acute lymphocytic leukemia | MNDR-E-MI-17076 |
MNDR | hsa-miR-152-3p | Ovarian epithelial cancer | MNDR-E-MI-17077 |
MNDR | hsa-miR-152-3p | Nasopharyngeal cancer | MNDR-E-MI-17078 |
MNDR | hsa-miR-152-3p | Prostatic neoplasms | MNDR-E-MI-17079 |
MNDR | hsa-miR-152-3p | Epstein-barr virus infections | MNDR-E-MI-17080 |
MNDR | hsa-miR-152-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-17081 |
MNDR | hsa-miR-152-3p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-17082 |
MNDR | hsa-miR-152-3p | Stroke lacunar | MNDR-E-MI-17083 |
MNDR | hsa-miR-152-3p | Breast cancer her3+ negative | MNDR-E-MI-17084 |
MNDR | hsa-miR-152-3p | High grade dysplastic nodule | MNDR-E-MI-17085 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ADAM17 | Homo sapiens | RR00040511 |
TOP